Financhill
Buy
60

RHHBY Quote, Financials, Valuation and Earnings

Last price:
$44.06
Seasonality move :
3.03%
Day range:
$43.95 - $44.31
52-week range:
$29.20 - $44.31
Dividend yield:
0%
P/E ratio:
30.82x
P/S ratio:
4.05x
P/B ratio:
8.01x
Volume:
7.3M
Avg. volume:
3.9M
1-year change:
35.54%
Market cap:
$281.5B
Revenue:
$70.9B
EPS (TTM):
$1.44

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RHHBY
Roche Holding AG
$16.9B -- -- -- $46.29
AZN
AstraZeneca PLC
$14.2B $1.04 8.37% 57.32% $85.10
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,006.63
NVO
Novo Nordisk AS
$11.5B $0.80 22.5% 10.09% $112.90
NVS
Novartis AG
$12.8B $1.76 6.82% 57% $109.37
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RHHBY
Roche Holding AG
$44.24 $46.29 $281.5B 30.82x $1.35 0% 4.05x
AZN
AstraZeneca PLC
$77.39 $85.10 $239.9B 34.32x $1.05 2% 4.47x
LLY
Eli Lilly and
$824.76 $1,006.63 $740.8B 70.43x $1.50 0.66% 16.55x
NVO
Novo Nordisk AS
$80.15 $112.90 $355.8B 24.41x $0.52 1.81% 8.50x
NVS
Novartis AG
$112.22 $109.37 $221.6B 19.09x $3.87 3.45% 4.41x
PFE
Pfizer
$26.05 $31.32 $147.6B 18.48x $0.43 6.49% 2.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RHHBY
Roche Holding AG
52.17% 0.691 16.91% 1.19x
AZN
AstraZeneca PLC
41.27% -0.475 -- 0.74x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
NVO
Novo Nordisk AS
40.09% 0.871 3.51% 0.52x
NVS
Novartis AG
40.07% 0.604 15.32% 0.80x
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RHHBY
Roche Holding AG
-- -- 12.15% 23.8% -- --
AZN
AstraZeneca PLC
$12.2B $2B 9.88% 17.77% 14.07% $2B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
NVO
Novo Nordisk AS
$10.4B $5.2B 60.28% 86.85% 40.78% -$786.4M
NVS
Novartis AG
$10.2B $3.5B 16.91% 27.64% 26.26% $3.1B
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B

Roche Holding AG vs. Competitors

  • Which has Higher Returns RHHBY or AZN?

    AstraZeneca PLC has a net margin of -- compared to Roche Holding AG's net margin of 10.07%. Roche Holding AG's return on equity of 23.8% beat AstraZeneca PLC's return on equity of 17.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    AZN
    AstraZeneca PLC
    81.7% $0.48 $69.5B
  • What do Analysts Say About RHHBY or AZN?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 4.63%. On the other hand AstraZeneca PLC has an analysts' consensus of $85.10 which suggests that it could grow by 9.97%. Given that AstraZeneca PLC has higher upside potential than Roche Holding AG, analysts believe AstraZeneca PLC is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    AZN
    AstraZeneca PLC
    6 2 0
  • Is RHHBY or AZN More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.758%.

  • Which is a Better Dividend Stock RHHBY or AZN?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 0%. AstraZeneca PLC offers a yield of 2% to investors and pays a quarterly dividend of $1.05 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or AZN?

    Roche Holding AG quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. Roche Holding AG's net income of -- is lower than AstraZeneca PLC's net income of $1.5B. Notably, Roche Holding AG's price-to-earnings ratio is 30.82x while AstraZeneca PLC's PE ratio is 34.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.05x versus 4.47x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    4.05x 30.82x -- --
    AZN
    AstraZeneca PLC
    4.47x 34.32x $14.9B $1.5B
  • Which has Higher Returns RHHBY or LLY?

    Eli Lilly and has a net margin of -- compared to Roche Holding AG's net margin of 32.59%. Roche Holding AG's return on equity of 23.8% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About RHHBY or LLY?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 4.63%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 22.05%. Given that Eli Lilly and has higher upside potential than Roche Holding AG, analysts believe Eli Lilly and is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    LLY
    Eli Lilly and
    16 4 0
  • Is RHHBY or LLY More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock RHHBY or LLY?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or LLY?

    Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Roche Holding AG's net income of -- is lower than Eli Lilly and's net income of $4.4B. Notably, Roche Holding AG's price-to-earnings ratio is 30.82x while Eli Lilly and's PE ratio is 70.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.05x versus 16.55x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    4.05x 30.82x -- --
    LLY
    Eli Lilly and
    16.55x 70.43x $13.5B $4.4B
  • Which has Higher Returns RHHBY or NVO?

    Novo Nordisk AS has a net margin of -- compared to Roche Holding AG's net margin of 32.95%. Roche Holding AG's return on equity of 23.8% beat Novo Nordisk AS's return on equity of 86.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    NVO
    Novo Nordisk AS
    84.8% $0.91 $33.4B
  • What do Analysts Say About RHHBY or NVO?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 4.63%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 40.86%. Given that Novo Nordisk AS has higher upside potential than Roche Holding AG, analysts believe Novo Nordisk AS is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is RHHBY or NVO More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

  • Which is a Better Dividend Stock RHHBY or NVO?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.81% to investors and pays a quarterly dividend of $0.52 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or NVO?

    Roche Holding AG quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Roche Holding AG's net income of -- is lower than Novo Nordisk AS's net income of $4B. Notably, Roche Holding AG's price-to-earnings ratio is 30.82x while Novo Nordisk AS's PE ratio is 24.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.05x versus 8.50x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    4.05x 30.82x -- --
    NVO
    Novo Nordisk AS
    8.50x 24.41x $12.2B $4B
  • Which has Higher Returns RHHBY or NVS?

    Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 20.79%. Roche Holding AG's return on equity of 23.8% beat Novartis AG's return on equity of 27.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
  • What do Analysts Say About RHHBY or NVS?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 4.63%. On the other hand Novartis AG has an analysts' consensus of $109.37 which suggests that it could fall by -2.54%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    NVS
    Novartis AG
    0 9 2
  • Is RHHBY or NVS More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.99%.

  • Which is a Better Dividend Stock RHHBY or NVS?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.45% to investors and pays a quarterly dividend of $3.87 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or NVS?

    Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.8B. Notably, Roche Holding AG's price-to-earnings ratio is 30.82x while Novartis AG's PE ratio is 19.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.05x versus 4.41x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    4.05x 30.82x -- --
    NVS
    Novartis AG
    4.41x 19.09x $13.6B $2.8B
  • Which has Higher Returns RHHBY or PFE?

    Pfizer has a net margin of -- compared to Roche Holding AG's net margin of 2.31%. Roche Holding AG's return on equity of 23.8% beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About RHHBY or PFE?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 4.63%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 20.22%. Given that Pfizer has higher upside potential than Roche Holding AG, analysts believe Pfizer is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    PFE
    Pfizer
    6 13 1
  • Is RHHBY or PFE More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock RHHBY or PFE?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

  • Which has Better Financial Ratios RHHBY or PFE?

    Roche Holding AG quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Roche Holding AG's net income of -- is lower than Pfizer's net income of $410M. Notably, Roche Holding AG's price-to-earnings ratio is 30.82x while Pfizer's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.05x versus 2.33x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    4.05x 30.82x -- --
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock